| Autor: |
Carmelo Nucera, S. Ananth Karumanchi, Jack Lawler, Joanne E. Murphy-Ullrich, Manoj Bhasin, Tracey Sciuto, Ann M. Dvorak, John Clohessy, Jennifer N. Sims, Soumya Ullas, Danica M. Vodopivec, Zeus A. Antonello, Swati S. Bhasin, Peter M. Sadow, Agnes S. Lo, Alessandro Prete |
| Rok vydání: |
2023 |
| Popis: |
Suppl. Figure 1 Drug dose-effect analysis in BRAFWT/V600E-KTC1 cells Suppl.Figure 2 Dose-effect analysis of vemurafenib and sorafenib on pericyte viability. Suppl. Figure 3 BRAFWT/WT-TPC1 cells viability assay. Suppl. Figure 4 ELISA analysis of cytokines secretion in pericytes, and PTC cells harboring the heterozygous BRAFWT/V600E mutation or with BRAFWT/WT. Suppl. Figure 5 Effects of pericyte secretome in BRAFWT/WT-TPC1 cells. Suppl. Figure 6 Analysis of secreted TSP-1 levels in PTC cells harboring the heterozygous BRAFWT/V600E mutation or with BRAFWT/WT treated with shTSP-1 or shGFP (control) pericyte secretome. Suppl. Figure 7 Effects of shTSP-1 pericyte secretome in BRAFWT/WT-TPC1 cells. Suppl. Figure 8 Viability assay in the presence of SRI31277 in PTC cells and pericytes. Suppl. Figure 9 Effects of the small molecule SRI31277 in PTC cells with BRAFWT/WT. Suppl. Figure 10 THBS1 (TSP-1) mRNA expression levels in PTC samples harboring both BRAFWT/V600E and hTERT mutations compared to BRAFWT/V600E-PTC samples. Suppl. Figure 11 THBS1 (TSP-1) mRNA expression levels in PTC samples harboring both BRAFWT/V600E and hTERT mutations compared to BRAFWT/WT-PTC samples. Suppl. Figure 12 THBS1 (TSP-1) gene regulatory networks pathways in PTC harboring BRAFWT/V600E and hTERT mutations compared to BRAFWT/WT-PTC clinical samples. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
